Inhibition of the autocrine IL-6–JAK2–STAT3–calprotectin axis as targeted therapy for HR(−)/HER2(+) breast cancers

HER2-positive (HER2(+)) breast adenocarcinomas are a heterogeneous group in which hormone receptor (HR) status influences therapeutic decisions and patient outcome. By combining genome-wide RNAi screens with regulatory network analysis, we identified STAT3 as a critically activated master regulator...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Genes Dev
Autori principali: Rodriguez-Barrueco, Ruth, Yu, Jiyang, Saucedo-Cuevas, Laura P., Olivan, Mireia, Llobet-Navas, David, Putcha, Preeti, Castro, Veronica, Murga-Penas, Eva M., Collazo-Lorduy, Ana, Castillo-Martin, Mireia, Alvarez, Mariano, Cordon-Cardo, Carlos, Kalinsky, Kevin, Maurer, Matthew, Califano, Andrea, Silva, Jose M.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Cold Spring Harbor Laboratory Press 2015
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4536311/
https://ncbi.nlm.nih.gov/pubmed/26227964
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/gad.262642.115
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi